These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 5317539)

  • 21. Treatment and prophylaxis of arthropathy in severe hemophilia.
    Ahlberg A
    Clin Orthop Relat Res; 1967; 53():135-46. PubMed ID: 5586853
    [No Abstract]   [Full Text] [Related]  

  • 22. Specific therapy in hemophilia.
    Hutaff LW
    N C Med J; 1973 Mar; 34(3):193-6. PubMed ID: 4510809
    [No Abstract]   [Full Text] [Related]  

  • 23. [The dosage of antihemophilic globulin, or antihemophilic plasma as well as Cohn's fraction I in factor VIII deficiency].
    Hrubisková K
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1970; 93(3):363-8. PubMed ID: 4195283
    [No Abstract]   [Full Text] [Related]  

  • 24. Absence of hepatitis after treatment with a pasteurized factor VIII concentrate in patients with hemophilia and no previous transfusions.
    Schimpf K; Mannucci PM; Kreutz W; Brackmann HH; Auerswald G; Ciavarella N; Mösseler J; DeRosa V; Kraus B; Brueckmann C
    N Engl J Med; 1987 Apr; 316(15):918-22. PubMed ID: 3102963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma fractions rich in factor VIII.
    Deutsch E; Fischer M
    Bibl Haematol; 1968; 29():1094-103. PubMed ID: 5303857
    [No Abstract]   [Full Text] [Related]  

  • 26. Dose requirement for replacement therapy in hemophilia A.
    Allain JP
    Thromb Haemost; 1979 Oct; 42(3):825-31. PubMed ID: 505399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Haemophilia.
    Biggs R
    Proc R Soc Med; 1969 Sep; 62(9):913-4. PubMed ID: 4241884
    [No Abstract]   [Full Text] [Related]  

  • 28. Pre-assayed AHF concentrate therapy for hemophilia.
    Peterson CA; Borucki DT; Austin G
    Bibl Haematol; 1968; 29():1160-5. PubMed ID: 5303858
    [No Abstract]   [Full Text] [Related]  

  • 29. [Substitutive treatment of hemopjolia A using a new factor VIII concentrate].
    Allain JP; Steinbuch M; Meunier L; Muller JY; Soulier JP
    Nouv Presse Med; 1976 Apr; 5(16):1047-50. PubMed ID: 1272773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in the care and treatment of children with hemophilia.
    Manco-Johnson MJ
    Adv Pediatr; 2010; 57(1):287-94. PubMed ID: 21056743
    [No Abstract]   [Full Text] [Related]  

  • 31. [Current status of the preparation and use of antihemophilic fractions in France. (Their use in surgery in hemophilia)].
    Ménaché D; Josso F; Steinbuch M; Soulier JP
    Transfusion (Paris); 1966; 9(3):237-44. PubMed ID: 5969559
    [No Abstract]   [Full Text] [Related]  

  • 32. [Occurrence of serum hepatitis following the administration of Cohn's fraction I or fibrinogen and antihemophilic globulin (AHG) respectively].
    Fábryová L; Hrubisko M
    Vnitr Lek; 1970 Feb; 16(2):123-6. PubMed ID: 5309309
    [No Abstract]   [Full Text] [Related]  

  • 33. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.
    McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR
    Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII.
    Nilsson IM; Berntorp E; Zettervall O
    N Engl J Med; 1988 Apr; 318(15):947-50. PubMed ID: 3127711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P; Plamenová I; Hollý P; Stasko J
    Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [in vivo reappearance of injected cryoprecopitate (factor VIII concentrates) in patients with hemophilia A].
    Kuble M; Wegner H; Cron D
    Z Gesamte Inn Med; 1973 Oct; 28(20):608-14. PubMed ID: 4767194
    [No Abstract]   [Full Text] [Related]  

  • 37. [Long-term treatment of hemophilia A with plasma fractions].
    Mey U; Gaerisch F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1970; 93(3):357-62. PubMed ID: 4195282
    [No Abstract]   [Full Text] [Related]  

  • 38. [Determination of factor VIII inhibitor in hemophiliacs].
    Mancini AF; Rosito P; Paolucci G
    Minerva Pediatr; 1976 Nov; 28(36):2181-5. PubMed ID: 995099
    [No Abstract]   [Full Text] [Related]  

  • 39. Management of musculo-skeletal complications of hemophilia.
    Srivastava RK; Sinha RS; Mehrotra V
    Indian Pediatr; 1984 Dec; 21(12):965-70. PubMed ID: 6442986
    [No Abstract]   [Full Text] [Related]  

  • 40. [Acquired hemophilia. Apropos of a case report with a fatal course].
    de Moerloose P; Tissot JD; Reber G; Schifferli J; Vogel J; Bouvier CA
    Schweiz Med Wochenschr; 1988 Oct; 118(42):1542-5. PubMed ID: 3144037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.